Content area
Full Text
The FDA has approved the first treatment for nocturnal polyuria. Desmopressin is a 9-amino synthetic analog of the pituitary hormone, vasopressin. Other formulations are approved for diabetes insipidus, primary nocturnal enuresis, hemophilia A, and von Willebrand disease (type 1). It is marketed as Noctiva nasal spray.
INDICATION
Desmopressin nasal spray is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least twice per night to void.1
DOSAGE
For patient < 65 years of age who are not at risk for hyponatremia, the dose is one spray (1.66 mcg) in either nostril nightly approximately 30 minutes before going to bed.1 For those ≥ 65 years age or younger patients at risk for hyponatremia, the dose is 0.83 mcg nightly. Clinicians may increase the dose to 1.66 mcg after at least seven days if needed, provided serum sodium has remained normal. The nasal spray must be primed before initial use and if not used for more than three days. Desmopressin acetate is available as 1.66 mcg per...